Dr. Christopher H. Chay, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,082
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NC license 9701282 -
Allergy & Immunology Physician
NC license 97-01282 -
Hematology (Internal Medicine) Physician
NC license 9701282 -
Medical Oncology Physician
NC license 9701282
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Mission Hospital and Asheville Surgery Ce Asheville, NC
- Pardee Hospital Henderson County Hendersonville, NC
- Adventhealth Hendersonville Hendersonville, NC
- The Mcdowell Hospital Marion, NC
- Transylvania Regional Hospital, Inc Brevard, NC
Medical groups
- American Oncology PArtners PA (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,082
- Services billed
- 130,308
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 12,600 | 35 |
| Injection, nivolumab, 1 mg | 10,800 | 14 |
| Injection, denosumab, 1 mg | 7,260 | 43 |
| Injection, paclitaxel, 1 mg | 6,483 | 20 |
| Injection, aprepitant, 1 mg | 5,200 | 31 |
| Injection, oxaliplatin, 0.5 mg | 5,100 | 11 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 4,320 | 12 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,870 | 28 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 2,190 | 12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,108 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Asheville, NC | 300 |
| Abiraterone Acetate | 226 |
| Xtandi (enzalutamide) | 95 |
| Ondansetron Hcl Other prescribers in Asheville, NC | 80 |
| Gabapentin Other prescribers in Asheville, NC | 75 |
| Letrozole Other prescribers in Asheville, NC | 74 |
| Bicalutamide | 71 |
| Eliquis (apixaban) Other prescribers in Asheville, NC | 67 |
| Dexamethasone Other prescribers in Asheville, NC | 62 |
| Ibrance (palbociclib) | 60 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 64 payments worth $2,511 in total to this clinician.
| Caris Mpi, Inc. | $1,136 |
|---|---|
| Novartis Pharmaceuticals Corporation | $195 |
| E.r. Squibb & Sons, L.l.c. | $133 |
| Janssen Biotech, Inc. | $127 |
| AbbVie Inc. | $108 |
| Merck Sharp & Dohme LLC | $83.00 |
| Beone Medicines USA, Inc. | $77.59 |
| Bayer HealthCare Pharmaceuticals Inc. | $68.07 |
| Food and Beverage | $1,611 |
|---|---|
| Consulting Fee | $900 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Caris Mpi, Inc. Aug 26, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $154,854 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
Eli Lilly and Company - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493 - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chem…
Ipsen Bioscience Inc. · NCT04083275 - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Ipsen Bioscience Inc. · Completed · NCT04083235
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.